Table 2 Post-treatment rates of ANA-positive conversion and APS autoantibody positivity in psoriasis patients categorized by treatment group.
From: Prevalence of antiphospholipid autoantibodies associated with biologics treatment for psoriasis
TNFi (n = 170) | IL-17i (n = 60) | IL-23i (n = 56) | P value | |
|---|---|---|---|---|
ANA-positive conversion rates (titers higher than 1:40) | 82/122 (67.2%) | 8/31 (25.8%) | 9/26 (34.6%) | < .001a |
ANA pattern No. (%) | ||||
Centromere type | 2/82 (2.4%) | 0/8 (0.0%) | 0/9 (0.0%) | 1 |
Homogeneous type | 63/82 (76.8%) | 4/8 (50.0%) | 4/9 (4.4%) | .04 |
Nucleolar type | 25/82 (30.5%) | 2/8 (25.0%) | 3/9 (33.3%) | 1 |
Speckled type | 55/82 (67.1%) | 7/8 (87.5%) | 7/9 (77.8%) | .57 |
ANA-positive conversion rates (titers higher than 1:320) | 30/157 (19.1%) | 0/39 (0.0%) | 1/34 (2.9%) | < .001 b |
ANA pattern No. (%) | ||||
Centromere type | 1/30 (3.3%) | NA | 0/1 (0.0%) | 1 |
Homogeneous type | 27/30 (90.0%) | NA | 0/1 (0.0%) | .13 |
Nucleolar type | 5/30 (16.7%) | NA | 0/1 (0.0%) | 1 |
Speckled type | 5/30 (16.7%) | NA | 0/1 (0.0%) | 1 |
Duration from the initiation of biologics to ANA-positive conversion (titers higher than 1:40), months (median, IQR) | 11.0 (5.0–29.8) | 14.5 (4.0–34.8) | 6.0 (1.0–24.0) | .63 |
Duration from the initiation of biologics to ANA-positive conversion (titers higher than 1:320), months (median, IQR) | 19.0 (8.0–35.3) | NA | 23.0 (12.0–26.5) | .22 |
APS autoantibody positivity, No. (%) | 54/113 (47.8%) | 14/37 (37.8%) | 5/28 (17.9%) | .01c |
LAC positivity, No. (%) | 41/113 (36.3%) | 12/37 (32.4%) | 4/28 (14.3%) | .07 |
aCL-IgG positivity, No. (%) | 19/108 (17.6%) | 2/32 (6.3%) | 1/26 (3.8%) | .10 |
aβ2GPI positivity, No. (%) | 4/108 (3.7%) | 0/33 (0.0%) | 0/26 (0.0%) | .78 |
